{
  "alleleExist":false,
  "dataVersion":"v4.5",
  "diagnosticImplications":[],
  "diagnosticSummary":"",
  "geneExist":true,
  "geneSummary":"B2M, a tumor suppressor and regulator of the immune system, is inactivated by mutation or deletion in various cancer types including non-Hodgkin's lymphoma.",
  "highestDiagnosticImplicationLevel":null,
  "highestFdaLevel":null,
  "highestPrognosticImplicationLevel":null,
  "highestResistanceLevel":null,
  "highestSensitiveLevel":null,
  "hotspot":false,
  "lastUpdate":"11/16/2020",
  "mutationEffect":{
    "citations":{
      "abstracts":[],
      "pmids":[
        "25294904",
        "1898655",
        "22137796"
      ]
    },
    "description":"B2M truncating mutations can produce several forms of C-terminally truncated proteins. Expression of B2M mutations in lymphoma cell lines resulted in decreased protein stability and increased cancer cell evasion of immune surveillance compared to wildtype (PMID: 1898655, 22137796, 25294904).",
    "knownEffect":"Likely Loss-of-function"
  },
  "oncogenic":"Likely Oncogenic",
  "otherSignificantResistanceLevels":[],
  "otherSignificantSensitiveLevels":[],
  "prognosticImplications":[],
  "prognosticSummary":"",
  "query":{
    "alteration":"T93Hfs*2",
    "alterationType":null,
    "consequence":"frameshift_variant",
    "entrezGeneId":567,
    "hgvs":null,
    "hugoSymbol":"B2M",
    "id":null,
    "proteinEnd":91,
    "proteinStart":91,
    "referenceGenome":"GRCh38",
    "svType":null,
    "tumorType":null
  },
  "treatments":[],
  "tumorTypeSummary":"",
  "variantExist":false,
  "variantSummary":"The B2M T93Hfs*2 mutation is likely oncogenic.",
  "vus":false
}